Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 104

1.

Portosystemic shunts and refractory hepatic encephalopathy: patient selection and current options.

Philips CA, Rajesh S, Augustine P, Padsalgi G, Ahamed R.

Hepat Med. 2019 Jan 25;11:23-34. doi: 10.2147/HMER.S169024. eCollection 2019. Review.

2.

Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies.

Marciano S, Díaz JM, Dirchwolf M, Gadano A.

Hepat Med. 2019 Jan 14;11:13-22. doi: 10.2147/HMER.S164250. eCollection 2019. Review.

3.

Practical steps to improve chronic hepatitis C treatment in people with opioid use disorder.

Roncero C, Ryan P, Littlewood R, Macías J, Ruiz J, Seijo P, Palma-Álvarez RF, Vega P.

Hepat Med. 2018 Dec 24;11:1-11. doi: 10.2147/HMER.S187133. eCollection 2019.

4.

Comparison of extracorporeal cellular therapy (ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure.

Duan Z, Xin S, Zhang J, You S, Chen Y, Liu H, Zheng S, Li Z, Ashley R, Millis M.

Hepat Med. 2018 Nov 16;10:139-152. doi: 10.2147/HMER.S180246. eCollection 2018.

5.

Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease.

Ahmed Z, Ren J, Gonzalez A, Ahmed U, Walayat S, Martin DK, Moole H, Yong S, Koppe S, Dhillon S.

Hepat Med. 2018 Oct 24;10:133-138. doi: 10.2147/HMER.S160616. eCollection 2018.

6.

Expert opinion on the management of hepatitis C infection in Kuwait.

Saad MF, Alenezi S, Asker H; Kuwait Hepatology Club.

Hepat Med. 2018 Sep 28;10:117-132. doi: 10.2147/HMER.S154842. eCollection 2018.

7.

Acute pediatric hyperammonemia: current diagnosis and management strategies.

Savy N, Brossier D, Brunel-Guitton C, Ducharme-Crevier L, Du Pont-Thibodeau G, Jouvet P.

Hepat Med. 2018 Sep 12;10:105-115. doi: 10.2147/HMER.S140711. eCollection 2018. Review.

8.

Progressive familial intrahepatic cholestasis: diagnosis, management, and treatment.

Gunaydin M, Bozkurter Cil AT.

Hepat Med. 2018 Sep 10;10:95-104. doi: 10.2147/HMER.S137209. eCollection 2018. Review.

9.

Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications.

Tawfik AK, Helmy A, Yousef M, Abou-Saif S, Kobtan A, Asaad E, Abd-Elsalam S.

Hepat Med. 2018 Sep 4;10:87-93. doi: 10.2147/HMER.S174267. eCollection 2018.

10.

Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment.

Abou Rached A, Abou Kheir S, Saba J, Assaf S, Kassis G, Sanchez Gonzalez Y, Ethgen O.

Hepat Med. 2018 Aug 28;10:73-85. doi: 10.2147/HMER.S160351. eCollection 2018.

11.

Management of refractory cirrhotic ascites: challenges and solutions.

Fukui H, Kawaratani H, Kaji K, Takaya H, Yoshiji H.

Hepat Med. 2018 Jul 3;10:55-71. doi: 10.2147/HMER.S136578. eCollection 2018. Review.

12.

Biomarkers for primary biliary cholangitis: current perspectives.

Kouroumalis E, Samonakis D, Voumvouraki A.

Hepat Med. 2018 Jun 18;10:43-53. doi: 10.2147/HMER.S135337. eCollection 2018. Review.

13.

Grazoprevir/elbasvir for the treatment of adults with chronic hepatitis C: a short review on the clinical evidence and place in therapy.

Sulejmani N, Jafri SM.

Hepat Med. 2018 May 4;10:33-42. doi: 10.2147/HMER.S130103. eCollection 2018. Review.

14.

Effect of sitagliptin on hepatic histological activity and fibrosis of nonalcoholic steatohepatitis patients: a 1-year randomized control trial.

Alam S, Ghosh J, Mustafa G, Kamal M, Ahmad N.

Hepat Med. 2018 Apr 27;10:23-31. doi: 10.2147/HMER.S158053. eCollection 2018.

15.

Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies.

Mendes LC, Stucchi RS, Vigani AG.

Hepat Med. 2018 Apr 3;10:13-22. doi: 10.2147/HMER.S125234. eCollection 2018. Review.

16.

Hepatic encephalopathy: current challenges and future prospects.

Swaminathan M, Ellul MA, Cross TJ.

Hepat Med. 2018 Mar 22;10:1-11. doi: 10.2147/HMER.S118964. eCollection 2018. Review.

17.

Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort.

Kutala BK, Mouri F, Castelnau C, Bouton V, Giuily N, Boyer N, Asselah T, Marcellin P.

Hepat Med. 2017 Dec 18;9:67-73. doi: 10.2147/HMER.S149578. eCollection 2017.

18.

PNPLA3 expression and its impact on the liver: current perspectives.

Bruschi FV, Tardelli M, Claudel T, Trauner M.

Hepat Med. 2017 Nov 6;9:55-66. doi: 10.2147/HMER.S125718. eCollection 2017. Review.

19.

Impact of hepatitis C virus genotype-4 eradication following direct acting antivirals on liver stiffness measurement.

Tag-Adeen M, Sabra AM, Akazawa Y, Ohnita K, Nakao K.

Hepat Med. 2017 Oct 6;9:45-53. doi: 10.2147/HMER.S142600. eCollection 2017.

20.

Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy.

Roggeri DP, Roggeri A.

Hepat Med. 2017 Sep 25;9:37-43. doi: 10.2147/HMER.S146438. eCollection 2017.

Supplemental Content

Loading ...
Support Center